Table 1.
Comparisons between vildagliptin and metformin groups on the clinic-anthropometric and laboratory variables at baseline.
| Vildagliptin (n = 19) |
Metformin (n = 19) |
p-Value | |
|---|---|---|---|
| Clinic-anthropometric aspects | |||
| Age (years) | 39.0 ± 5.3 | 39.8 ± 7.7 | 0.44 |
| Weight (kg) | 94.0 ± 14.0 | 99.5 ± 16.1 | 0.31 |
| BMI (Kg/m2) | 36.0 ± 3.0 | 38.5 ± 6.1 | 0.25 |
| Waist Circumference (cm) | 105.6 ± 10.5 | 106.55 ± 12.0 | 0.51 |
| Hip Circumference (cm) | 116.1 ± 9.0 | 122.7 ± 11.9 | 0.09 |
| WHR | 0.91 ± 0.05 | 0.88 ± 0.07 | 0.57 |
| Systolic BP (mmHg) | 131.5 ± 20.9 | 134.6 ± 27.2 | 0.75 |
| Diastolic BP (mmHg) | 84.0 ± 13.4 | 83.0 ± 13.1 | 0.97 |
| Mean BP (mmHg) | 100.0 ± 15.6 | 100.2 ± 17.2 | 0.86 |
| Fat mass (%) | 39.5 ± 3.9 | 41.1 ± 4.2 | 0.29 |
| Lean mass (%) | 60.4 ± 6.5 | 59.2 ± 6.1 | 0.30 |
| Laboratory aspects | |||
| Insulin (mIU/l) | 1.8 ± 0.9 | 1.9 ± 1.2 | 0.75 |
| PG (mg/dl) | 200.3 ± 95.1 | 190.3 ± 74.0 | 0.88 |
| Post-load PG (mg/dl) | 253.4 ± 60.9 | 255.9 ± 56.9 | 1.0 |
| HbA1c (%) | 8.0 ± 1.8 | 7.8 ± 2.0 | 0.64 |
| Total Cholesterol (mg/dl) | 183.9 ± 36.7 | 198.0 ± 37.8 | 0.18 |
| Triglycerides (mg/dl) | 161.0 ± 79.8 | 141.2 ± 78.7 | 0.28 |
| HDL-cholesterol (mg/dl) | 43.0 ± 8.2 | 46.7 ± 11.3 | 0.38 |
| LDL-cholesterol (mg/dl) | 108.6 ± 26.3 | 112.90 ± 25.9 | 0.13 |
| VLDL-cholesterol (mg/dl) | 32.3 ± 16.0 | 28.3 ± 15.7 | 0.29 |
| C-Reactive Protein (mg/dl) | 1.1 ± 1.4 | 0.9 ± 0.6 | 0.94 |
| GIP (pg/mL) | 24.3 ± 14.6 | 20.3 ± 12.3 | 0.32 |
| GLP-1 (pM/l)) | 1.1 ± 1.0 | 1.0 ± 0.7 | 0.98 |
| Glucagon (pg/mL) | 23.5 ± 20.7 | 31.5 ± 53.5 | 0.53 |
| LDLox (U/L) | 74.8 ± 31.3 | 62.1 ± 16.8 | 0.24 |
| Endothelin-1 (pg/mL) | 1.7 ± 0.5 | 1.6 ± 0.5 | 0.83 |
| DPP4act (uM/mL/min) | 9.4 ± 3.5 | 9.6 ± 3.7 | 0.86 |
Data are expressed as mean ± SD. BMI–body mass index; BP–blood pressure; HbA1c–glycated hemoglobin; PG–plasma glucose; TC–total cholesterol; TG–triglycerides; HDL–high-density lipoprotein; LDL–low-density lipoprotein; VLDL–very low-density lipoprotein; GIP–Glucose-dependent insulinotropic peptide; GLP-1–glucagon-like peptide-1; LDLox–oxidized low-density lipoprotein; DPP4act–Dipeptidyl peptidase-4 activity.